Novavax vaccine demonstrates 90% efficacy, 100% protection against moderate, severe disease
"Novavax COVID-19 Vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 Trial," the company said in a tweet.
Also Read | Coronavirus: India reports 70,421 new cases in 24 hours; lowest after 74 days
While releasing its Phase 3 trial details, the company said that the preliminary safety data from PREVENT-19 showed the vaccine to be generally well-tolerated.
Serious and severe adverse events were low in number and balanced between vaccine and placebo groups, it said, adding that no single adverse event term was reported by more than 1 percent of participants.
Also Read | US FDA rejects emergency use authorisation for Bharat Biotech’s vaccine Covaxin
Stanley C. Erck, President and Chief Executive Officer, Novavax, said that "Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines."
Biotech firm is planning to file for authorisation with the Food and Drug Administration in the third quarter of 2021.
Click here to follow PTC News on Twitter
-PTC News
